Cite
Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy.
MLA
Azar, Joseph H., et al. “Selective Suppression of de Novo SARS-CoV-2 Vaccine Antibody Responses in Patients with Cancer on B Cell-Targeted Therapy.” JCI Insight, vol. 8, no. 6, Mar. 2023. EBSCOhost, https://doi.org/10.1172/jci.insight.163434.
APA
Azar, J. H., Evans, J. P., Sikorski, M. H., Chakravarthy, K. B., McKenney, S., Carmody, I., Zeng, C., Teodorescu, R., Song, N.-J., Hamon, J. L., Bucci, D., Velegraki, M., Bolyard, C., Weller, K. P., Reisinger, S. A., Bhat, S. A., Maddocks, K. J., Denlinger, N., Epperla, N., … Rubinstein, M. P. (2023). Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell-targeted therapy. JCI Insight, 8(6). https://doi.org/10.1172/jci.insight.163434
Chicago
Azar, Joseph H, John P Evans, Madison H Sikorski, Karthik B Chakravarthy, Selah McKenney, Ian Carmody, Cong Zeng, et al. 2023. “Selective Suppression of de Novo SARS-CoV-2 Vaccine Antibody Responses in Patients with Cancer on B Cell-Targeted Therapy.” JCI Insight 8 (6). doi:10.1172/jci.insight.163434.